Navigation Links
ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09%
Date:12/4/2008

product in the U.S. in 2005. According to IMS data, Xibrom was the fastest-growing branded ophthalmic product (with sales greater than $10 million) in the nine-month period ended September 2008.

About ISTA Pharmaceuticals

ISTA Pharmaceuticals is an ophthalmic pharmaceutical company. ISTA's products and product candidates addressing the $4.7 billion. U.S. prescription ophthalmic industry include therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye. The Company currently markets three products and is developing a strong product pipeline to fuel future growth and market share. The Company's product development and commercialization strategy is to launch a new product every 12 to 18 months, thereby continuing its growth to become the leading niche ophthalmic pharmaceutical company in the U.S. For additional information regarding ISTA, please visit ISTA Pharmaceuticals' website at http://www.istavision.com.

Any statements contained in this press release which refer to future events or other non-historical matters are forward-looking statements. Without limiting the foregoing, but by way of example, statements contained in this press release related to planning to conduct a confirmatory Phase III trial for Xibrom and expecting to complete such trial in 2009, ISTA's expectation of bringing a new product to market every 12 to 18 months and becoming the leading niche ophthalmic pharmaceutical company are forward-looking statements. Except as required by law, ISTA disclaims any intent or obligation to update any forward-looking statements. These forward-looking statements are based on ISTA's expectations as of the date of this press release and are subject to risks and uncertainties that could cause actual results to differ materially. Important factors that could cause actual results to differ from current expectations include, a
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
2. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
3. Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin
4. Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia
5. Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia
6. Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351
7. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
8. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
9. VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease
10. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
11. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)...  Decision Resources Group finds that the laparoscopic device ... will increase to a value of over $4.3 billion ... in the large direct energy device market. In particular, ... due to the advantages they offer and as new ... Decision Resources Group,s coverage of the U.S. laparoscopic device ...
(Date:12/19/2014)... -- Baptist Health Lexington is the first facility in ... Fibrillation with Electrophysiology Services (EPS) Accreditation status from the Society ... the most common cardiac arrhythmia and has become recognized as ... stroke and possible death. More than 5 million patients in ... and the numbers are rapidly increasing as the population ages. ...
(Date:12/19/2014)... LYON, France , Dec. 19, 2014 ... ) and Adocia (Euronext Paris: FR0011184241 – ADOC) today ... ultra-rapid insulin, known as BioChaperone Lispro, for treatment in ... Lispro relies on Adocia,s proprietary BioChaperone® technology and is ... Adocia will develop BioChaperone Lispro with the goal of ...
Breaking Medicine Technology:U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3
(Date:12/19/2014)... Texas (PRWEB) December 19, 2014 ... exhibited at the AMSUS Society for Federal Health ... the locum tenens industry to military and federal ... attended the National Veterans Small Business Engagement (NVSBE) ... Tenens continues to be a vital solution in ...
(Date:12/19/2014)... Dec. 18, 2014 (HealthDay News) -- A new study ... moderate to severe hot flashes and night sweats -- ... Hot flashes are common during menopause, affecting about ... also affect women after menopause, since they then face ... "Our findings suggest women who exhibit moderate or severe ...
(Date:12/19/2014)... Randy Dotinga HealthDay Reporter ... painkillers, including ibuprofen, might slightly reduce your risk of ... Use of ibuprofen (Advil, Motrin) and naproxen (Aleve) appear ... by 15 percent, the researchers concluded after reviewing nine ... by sun exposure. These painkillers "have ...
(Date:12/19/2014)... Reinberg HealthDay Reporter THURSDAY, ... on one leg for at least 20 seconds you may ... Difficulty standing on one leg may indicate that small strokes ... for more serious strokes is high, the investigators reported online ... showing instability while standing on one leg, as well as ...
(Date:12/17/2014)... Mass. (PRWEB) December 17, 2014 ... of Osteopathic Medicine (ACOM), which welcomed its inaugural ... Desktop Infrastructure (VDI) to seamlessly support bring your ... – and teaching – experience. The solution, comprised ... NetScaler , Dell server and storage infrastructure ...
Breaking Medicine News(10 mins):Health News:Consilium Staffing Increasing Awareness of Locum Tenens through Conference Appearances 2Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 3Health News:Can You Balance on One Leg? You May Have Lower Stroke Risk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 3
... issued Global Air Quality Guidelines on Thursday so as to ... each year with most of the deaths occurring in developing ... air quality in the cities. A statement issued by the ... could be saved every year by bringing down the PM10 ...
... in Andhra Pradesh carry the HIV virus, which is passed on ... Society (APSACS) has come to the aid of such infants, suffering ... the society strives to realize infant births sans HIV by the ... the country, the group has lined up the Telugu Network of ...
... (RPCI), the wholly owned subsidiary of Indian pharma major ... with Janssen-Ortho Inc. (JOI) for marketing of its generic ... be commercialised by RPCI, Fentanyl would be sold under ... with Janssen-Ortho Inc, the company said in a statement ...
... and three arms on the Indonesian resort island of Bali ... ,"It's a tough case, but so far they are stable," ... the Bali capital Denpasar, told DPA., ,"We are still ... action yet," he said, adding that in medical terms the ...
... Medical Journal reports that vaccination against the sexually transmitted virus ... in Europe//. ,All the girls of the age ... GlaxoSmithKline or with Gardasil of Merck & Co., according to ... in the U.S. in which, a bill passed by the ...
... Australia are going full steam to counter skin diseases ... aim to prevent the spread of tinea(fungal infections),scabies and ... the ,far flung interior aboriginal communities and to mete ... , ,Poverty and unhygienic living conditions facilitate the ...
Cached Medicine News:
... access. Hollow stylet design with ... with two-part needle. Initial flashback ... maintaining thumb position on stylet. ... of the stylet. Supplied sterile ...
Used for arterial and venous punctures. The tapered hub design of the catheter facilitates wire guide introduction. Supplied sterile in peel-open packages. Intended for one-time use....
Used for placement of .035 inch (0.89 mm) or .038 inch (0.97 mm) diameter wire guides into the vascular system when a small 24 gage needle stick is desired....
Used for percutaneous introduction of balloon, electrode and closed or non-tapered end catheters for vascular and non-vascular use....
Medicine Products: